Dianthus Therapeutics (Dianthus Therapeutics) EBIT per Share : $-5.60 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics EBIT per Share?

Dianthus Therapeutics's EBIT per Share for the three months ended in Mar. 2024 was $-0.70. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-5.60.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Dianthus Therapeutics's EBIT per Share or its related term are showing as below:

DNTH's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Dianthus Therapeutics's EBIT for the three months ended in Mar. 2024 was $-17.84 Mil.

Dianthus Therapeutics EBIT per Share Historical Data

The historical data trend for Dianthus Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics EBIT per Share Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

EBIT per Share

-0.88

-2.01

-9.35

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial			-0.72	-0.52	-4.03	-0.87	-0.70

Dianthus Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Dianthus Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-48.174	/	5.153
=	-9.35

Dianthus Therapeutics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-17.844	/	25.665
=	-0.70

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.60

Dianthus Therapeutics (NAS:DNTH) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Dianthus Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

87E:Germany

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023